A Multicenter, Randomized, Controlled Trial of Electroacupuncture for Perimenopause Women with Mild-Moderate Depression

Table 2

The change from baseline of HAMD-17 and MENQOL score.

Outcome	EA ()	ES ()	Between-group differences (95% CI)	P
Change from baseline; in HAMD (Mean ± SD)
Week 4	−2.64 ± 3.10	−2.38 ± 2.76	−0.25 ()	0.498
Week 8	−4.62 ± 3.65	−4.10 ± 3.64	−0.55 ()	0.226
Week 12	−6.07 ± 4.68	−5.13 + 4.48	−1.03 ()	0.055
Week 16	−6.60 ± 4.58	−5.30 ± 4.38	−1.36 (−0.31)	0.012
Week 24	−7.84 ± 4.83	−5.65 ± 4.26	−2.23 (−1.15)	0.000
Change from baseline; in MENQOL (Mean ± SD)
Week 4	−10.21 ± 13.73	−7.39 ± 8.62	−2.84 ()	0.057
Week 8	−18.09 ± 17.97	−14.16 ± 13.63	−3.95 (−0.01)	0.050
Week 12	−23.18 ± 22.45	−19.03 ± 17.25	−4.32 ()	0.080
Week 16	−24.44 ± 22.44	−19.34 ± 18.08	−5.20 (−0.28)	0.039
Week 20	−27.43 ± 22.64	−19.42 ± 18.65	−8.12 (−3.06)	0.002
Week 24	−28.94 ± 23.22	−20.04 ± 18.98	−8.97 (−3.81)	0.001

EA means electroacupuncture treatment; ES means escitalopram treatment. Data is given as the mean ± standard deviation.